Show simple item record

dc.contributor.authorH. Abu-Id, Mario
dc.contributor.authorH. Warnke, Patrick
dc.contributor.authorGottschalk, Joachim
dc.contributor.authorSpringer, Ingo
dc.contributor.authorWiltfang, Jorg
dc.contributor.authorAcil, Yahya
dc.contributor.authorA.J. Russo, Paul
dc.contributor.authorKreusch, Thomas
dc.date.accessioned2017-05-03T14:41:51Z
dc.date.available2017-05-03T14:41:51Z
dc.date.issued2008
dc.identifier.issn10105182
dc.identifier.doi10.1016/j.jcms.2007.06.008
dc.identifier.urihttp://hdl.handle.net/10072/65182
dc.description.abstractIntroduction Bisphosphonates (BPs) have transformed our ability to treat certain malignancies, osteoporosis and hypercalcaemia. This class of drug is assumed to be well tolerated by most. There are some important caveats to this assumption, however, one of the significances being the risk of osteonecrosis of the jaw (ONJ). Material and methods This multi-centre retrospective study examined the role of different BPs on the development of ONJ, its clinical presentation and the efficacy of various treatment modalities, comparing these findings with the available literature. Results A total of 78 patients from 17 centres were identified with ONJ. A majority of patients identified with ONJ had used Pamidronate or Zoledronate (93.6%) intravenously. 94.9% of patients had received BP in the course of treatment for malignancies and a majority had also received prior chemotherapy or exogenous steroids. 82.1% of patients had received BP for more than 1 year. The mean time from the introduction of BP to the development of ONJ in 24 patients from our department was 31.8 months. Conclusions The most common intraoral manifestation was exposed necrotic jawbone. Tooth extractions and oral surgical intervention appear to place patients on BP therapy at risk of ONJ, especially after intravenous BP treatments. ONJ proved in this study to be remarkably refractory to treatment, with radical resection being the only curative approach. We recommend that all patients receive necessary dental treatment prior to commencing BP therapy.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherChurchill Livingstone
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom95
dc.relation.ispartofpageto103
dc.relation.ispartofissue2
dc.relation.ispartofjournalJournal of Cranio-Maxillofacial Surgery
dc.relation.ispartofvolume36
dc.rights.retentionY
dc.subject.fieldofresearchDentistry not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchDentistry
dc.subject.fieldofresearchcode110599
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1105
dc.title"Bis-phossy jaws" - High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorWarnke, Patrick H.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record